 |
|

Search "Crohn’s disease"
|

|
Crohn’s disease | |
|
About 35 pages (10,559 words) in 3 products |
|

Encyclopedia and Summary Information
summary from source:

Crohn's Disease Summary
1,479 words, approx. 5 pages Crohn's disease (pronounced krohnz) is a type of inflammatory bowel disease. It results in swelling of the intestinal tract. It may also restrict the function of the intestinal tract. The term inflammatory bowel diseases (IBD) refers to a...
summary from source:

Cronkite, Walter Summary
1,935 words, approx. 7 pages Born November, 4, 1916St. Joseph, Missouri Journalist, television newsperson Walter Cronkite. © Walter Cronkite worked in television news from its beginnings in the early 1950s. He...
summary from source:

Crohn’s disease Information
7,145 words, approx. 24 pages
 Crohn's disease (also known as regional enteritis) is a chronic, episodic, inflammatory condition of the gastrointestinal tract characterized by transmural inflammation (affecting the entire wall of the involved bowel) and skip lesions (areas of...




summary from source:
 AP News
FDA OKs Tysabri to fight Crohn's disease
1/14/2008: 283 words, approx. 1 pages Tysabri, a treatment for multiple sclerosis made by Biogen Idec Inc. and Elan Corp., received regulatory approval on Monday for use among patients with a severe intestinal disorder.The Food and Drug Administration approved Tysabri for use in patients with moderate to severe Crohn's disease who...
summary from source:
 AP Features
FDA clears Biogen's and Elan's Tysabri for additional use against Crohn's disease
1/14/2008: 324 words, approx. 1 pages Tysabri, a treatment for multiple sclerosis made by Biogen Idec Inc. and Elan Corp., received regulatory approval on Monday for use among patients with a severe intestinal disorder.The Food and Drug Administration approved Tysabri for use in patients with moderate to severe Crohn's disease who...
summary from source:
 AP Features
U.S. regulators to consider use of Tysabri drug for victims of Crohn's disease
5/29/2007: 323 words, approx. 1 pages Elan Corp. PLC and Biogen Idec Inc., the makers of Tysabri, announced Tuesday that U.S. regulators would soon review the drug for its possible use by sufferers of the gastrointestinal ailment Crohn's disease.Both companies said two review committees of the U.S. Food and Drug Administration...
summary from source:
 AP Features


|
Crohn’s disease | |
|
About 35 pages (10,559 words) in 3 products |
|
|
|


|
|  |
 |
|  |